BRIEF published on 01/24/2025 at 08:05, 1 year 9 months ago Median Technologies Secures Up to €47.5 Million for AI Lung Cancer Diagnostics European Investment Bank Median Technologies AI Lung Cancer Diagnostics Eyonis™ EU And US Commercialization
PRESS RELEASE published on 01/24/2025 at 08:00, 1 year 9 months ago Inside Information / Other news releases Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization. New financing & operational enhancements drive profitability & extend cash runway into Q4, 2025 AI Commercialization Median Technologies Lung Cancer Diagnostic Eyonis
BRIEF published on 11/26/2024 at 17:50, 1 year 11 months ago Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024 Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening
PRESS RELEASE published on 11/26/2024 at 17:45, 1 year 11 months ago Inside Information / Other news releases Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at RSNA 2024. Company presents latest developments and REALITY study results to experts in medical imaging conference AI-powered Median Technologies Eyonis LCS RSNA 2024 Lung Cancer Diagnostic
BRIEF published on 10/30/2024 at 17:50, 2 years ago Median Technologies and AI in lung cancer screening Artificial Intelligence Medical Technologies Lung Cancer Webconférence 2024 Medical Screening
BRIEF published on 10/07/2024 at 17:50, 2 years 1 month ago Status of voting rights and capital of Median Technologies as of September 30, 2024 Voting Rights Capital Actions Median Technologies September 30, 2024
BRIEF published on 09/06/2024 at 17:50, 2 years 2 months ago Modification of the rights attached to the categories of shares of Median Technologies Voting Rights Capital Actions Median Technologies Modification Of Rights
PRESS RELEASE published on 09/06/2024 at 17:45, 2 years 2 months ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and shares as of August 31, 2024, in accordance with regulatory requirements. Company uses AI for cancer diagnoses and treatments globally Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 09/04/2024 at 17:50, 2 years 2 months ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 2 years 2 months ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
Published on 11/10/2026 at 12:00, 8 minutes ago High Tide Produces 67.3% Fe Direct Reduction Quality Concentrate from Labrador West Pilot Plant Program
Published on 11/10/2026 at 11:46, 22 minutes ago Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
Published on 11/10/2026 at 11:00, 1 hour 8 minutes ago 3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
Published on 11/10/2026 at 08:00, 4 hours 8 minutes ago PEL 82 - QatarEnergy to Acquire 25% Participating Interest from Chevron
Published on 11/10/2026 at 02:45, 9 hours 23 minutes ago Presentation to Zurich Precious Metals Summit
Published on 11/10/2026 at 11:16, 52 minutes ago Second drill rig mobilised as Lionheart construction ramps up
Published on 11/10/2026 at 11:04, 1 hour 4 minutes ago aap increases revenue by 2% in the third quarter of 2026 – on top of the already high prior-year level
Published on 11/10/2026 at 10:50, 1 hour 18 minutes ago German R&D Tax Credits: New Administrative Instruction by Federal Ministry of Finance Tightens Documentation Requirements
Published on 11/10/2026 at 10:09, 1 hour 59 minutes ago EQS-Adhoc: Emerald Horizon AG plans to raise approximately EUR 135 million in equity by 2028 and resolves first cash capital increase
Published on 11/10/2026 at 11:02, 1 hour 6 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of October 31, 2026
Published on 11/10/2026 at 07:00, 5 hours 8 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/09/2026 at 18:30, 17 hours 38 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 17:35, 18 hours 33 minutes ago Disclosure of transactions in own shares from November 2 to November 6, 2026
